Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022926 | 1.00 | MRGPRX4 (0.52) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL16834473 | 0.86 | MRGPRX4 (0.50) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL6117260 | 0.86 | CYP1A2 (0.53) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL7671391 | 0.86 | MRGPRX4 (0.52) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL1181244 | 0.84 | MAPT (0.51) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL22002661 | 0.84 | MRGPRX4 (0.58) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL22451835 | 0.84 | MRGPRX4 (0.51) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL21199935 | 0.84 | MRGPRX4 (0.51) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL18291840 | 0.84 | MRGPRX4 (0.51) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 | |
| SCHEMBL465719 | 0.84 | MRGPRX4 (0.54) | MRGPRX4PARP1MAPTCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082793-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. | 2025-03-13 | — | — | US | claimed |
| EP-4430040-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | Janssen Biotech, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| CN-118201925-A | Macrocyclic compounds and methods of making the same | 詹森生物科技公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2023084396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | JANSSEN BIOTECH, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4694981-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | MINDRANK AI LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20040048848-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2003066592-A1 | GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0946546-B1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PF MEDICAMENT (FR) | 2003-06-25 | — | — | EP | disclosed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | disclosed |
| EP-0946546-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998022459-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-05-28 | — | — | WO | disclosed |
| US-5559134-A | Leukotriene-B4 antagonists, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-24 | — | — | US | disclosed |
| WO-1995001346-A1 | CHELATING COMPOUNDS | AKZO NOBEL N.V. (NL) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | MRGPRX4 4524/4885PARP1 232/4885MAPT 3732/4885 |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | GLP1R, GIPR, GCGR | MRGPRX4 172/4885PARP1 3787/4885MAPT 3780/4885 |
| US-20250082793-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME | PAICS, CD47, FURIN | MRGPRX4 939/4885PARP1 1086/4885MAPT 1539/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | MRGPRX4 302/4885PARP1 2945/4885MAPT 4801/4885 |
| US-20040048848-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, PSEN1 | MRGPRX4 1342/4885PARP1 743/4885MAPT 314/4885 |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | MRGPRX4 331/4885PARP1 3935/4885MAPT 3889/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885PARP1 4260/4885MAPT 4716/4885 |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | ADORA1, ADORA3, ADORA2A | MRGPRX4 480/4885PARP1 1042/4885MAPT 3965/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | MRGPRX4 2105/4885PARP1 226/4885MAPT 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.